Similar articles

• Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo.

  Plunkett W, Alexander L, Chubb S, Loo TL. Plunkett W, et al. Biochem Pharmacol. 1979;28(2):201-6. doi: 10.1016/0006-2952(79)90504-5. Biochem Pharmacol. 1979. PMID: 426835 No abstract available.
• Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture.

  Cass CE, Tan TH, Selner M. Cass CE, et al. Cancer Res. 1979 May;39(5):1563-9. Cancer Res. 1979. PMID: 85484
• Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues.

  Plunkett W. Plunkett W. Ann N Y Acad Sci. 1985;451:150-9. doi: 10.1111/j.1749-6632.1985.tb27106.x. Ann N Y Acad Sci. 1985. PMID: 3907452 Clinical Trial. No abstract available.
• Inhibitors of adenosine deaminase.

  Agarwal RP. Agarwal RP. Pharmacol Ther. 1982;17(3):399-429. doi: 10.1016/0163-7258(82)90023-7. Pharmacol Ther. 1982. PMID: 6187032 Review. No abstract available.
• Inhibitors of adenosine deaminase and the development of antiviral agents.

  Cohen SS. Cohen SS. Ann N Y Acad Sci. 1985;451:204-14. doi: 10.1111/j.1749-6632.1985.tb27111.x. Ann N Y Acad Sci. 1985. PMID: 2416257 Review. No abstract available.